Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BGB-45035 Versus Placebo in Patients With Moderate to Severe Active Rheumatoid Arthritis

NCT07100938 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT07100938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07100938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BGB-45035 Versus Placebo in Patients With Moderate to Severe Active Rheumatoid Arthritis
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Terminated
Start date
August 21, 2025
Completion date
May 12, 2026
Enrollment
49 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis